Trizivir

POZ IRELAND

gpi@poz.iol.ie

Home
Basic Message
Laboratory Tests
Viral Load
When to start treatment?
Treatments
Anti-HIV Drugs
Drugs and Doses
Side Effects
Treatment Changes
Salvage Therapy
Infections
Vaccinations
Lipodystrophy
Micronutrition
Women & HIV
Glossary

TRIZIVIR

Approved for use in HIV infection in combination with other antiviral drugs.

DESCRIPTION: Trizivir® is a combination of three NRTIs: abacavir, 3TC (lamivudine) and AZT (zidovudine).

DOSE: One tablet twice a day. Each tab. contains 300 mg ABC, 150 mg 3TC and 300 mg AZT. Because of the fixed dosage , people weighing > 40 kg or with renal impairment should not take Trizivir.

SIDE EFFECTS: The most common side effects of Trizivir are the same as with Retrovir (AZT), Epivir (3TC), and abacavir (Ziagen). They include headache, upset stomach, nausea, and fatigue. See ABC, 3TC and AZT for listings. Trizivir is associated with fatal hypersensitivity reactions. Enlarged fatty liver and lactic acidosis, including fatal cases have been reported with the NARTIs.

RESISTANCE: See ABC, 3TC and AZT

DRUG INTERACTIONS: Trizivir should not be taken with ddC (zalcitabine, Hivid®) or with d4T (stavudine, Zerit®). Blood levels of 3TC may be increased by septrin.

See ABC, 3TC and AZT

ADVANTAGES	DISADVANTAGES
Simple regimen – low tablet numbers	Maybe less potent than PI or NNRTI containing combination
Appear to be associated with decreases in triglycerides and cholesterol	Hypersensitivity problems with ABC
Saves PI and NNRTI options	Possibility of increased NARTI toxicity with 3 NARTIs – mitochondrial toxicity

[ Abacavir ] [ ddI ] [ 3TC ] [ d4T ] [ ddC ] [ AZT ] [ Combivir ] [ Trizivir ] [ Emtricitabine ] [ Kivexa ]

[ Home ] [ Up ]

Copyright © 2005 Poz Ireland